New homegrown antimalarial drug to be approved in first half

Published: 2011-02-22 07:00:00

Updated: 2011-02-22 07:00:00

The Korea Food and Drug Administration is likely to approve Pyramax, an investigational antimalarial medicine developed by Shinpoong Pharmaceutical Co, possibly in the first half of this year.

Pyramax is a fixed-dose combination of pyronaridine and artesunate that has completed a program of cl...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK